Project Details
Description
A Randomized, Placebo-Controlled, Blind-Start, Single-Crossover Phase 3 Study to Assess the Efficacy and Safety of UX003 rhGUS Enzyme Replacement Therapy in Patients with MPS 7
Status | Finished |
---|---|
Effective start/end date | 11/13/14 → 6/1/16 |
Funding
- ULTRAGENYX PHARMACEUTICAL INC.
Fingerprint
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.